Preliminary results from the Sisonke, which have not been peer-reviewed, found that for people who had received one vaccine dose, the booster improved protection against hospitalization to 85 percent from 63 percent.
The study, carried out by the South African Medical Research Council compared 69,000 healthcare workers in South Africa to a group of unvaccinated South Africans.
The study’s authors said it provided “the first evidence of the effectiveness” of the Johnson & Johnson vaccine, known as Ad26.COV.2, when delivered six to nine months after first dose.“This data is important given the increased reliance on the Ad26.COV.2 vaccine in Africa,” the study said. "Data from the Sisonke 2 study confirm that the Johnson & Johnson Covid-19 booster shot provides 85 percent effectiveness against hospitalization in areas where omicron is dominant," Mathai Mammen, the global head of Janssen Research & Development, a pharmaceutical company owned by Johnson & Johnson, said in a statement.
"This adds to our growing body of evidence which shows that the effectiveness of the Johnson & Johnson Covid-19 vaccine remains strong and stable over time, including against circulating variants such as omicron and Delta.”
Thats nice.
Nobody: J& J: we got a booster, too No. We don't want it.